Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Summary

This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma. Radiation therapy uses high energy radiation to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after radiation therapy may kill more tumor cells.

Timeline

Start

2017-05-01

Primary completion

2024-11-15

Completion

2026-04-27

Drugs

Indications